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Studies using a longer time frame found a stronger association than studies using a shorter time 
frame and somatic items in depression measures are positively correlated with associations of 
depression with breast cancer incidence.  Thus, future studies should (a) ensure sufficient periods 
of time between the measurement of depression and the assessment of cancer, and (b) avoid 
measuring depression using somatic items. 
 




Purpose: A relationship between depression and the development of breast cancer has not been 
convincingly shown in the research conducted over the past three decades.   
Methods: In an effort to better understand the conflicting results, a review was conducted 
focusing on the methodological problems associated with this literature, including time frame 
between the assessment of depression and the diagnosis of breast cancer and the use of somatic 
items in measuring depression.  Fifteen breast cancer prospective studies were reviewed.   
Results: While twelve of the studies found positive associations between depression and breast 
cancer development, three studies found negative associations.  With regards to the predictive 
associations between depression and breast cancer incidence the findings revealed that (a) studies 
using a longer time frame found a stronger association than studies using a shorter time frame, 
and (b) studies utilizing depression measures that did not contain somatic items found a smaller 
association than studies utilizing depression measures that did contain these items.  
Conclusions: Future studies should ensure that sufficient periods of time between the 
measurement of depression and the assessment of cancer and avoid measuring depression using 
somatic items. 
 
Keywords: depression; time frame; somatic items; development; incidence; breast cancer 
 
DEPRESSION AND BREAST CANCER     4 
 
 
Breast cancer is consistently among the most prevalent and deadly forms of cancer.  
Although death rates from breast cancer have been steadily decreasing since 1990, it ranks 
second in cancer deaths among women (after lung cancer) and first in prevalence [1].  This might 
be one of the reasons for the longstanding interest in the effect of psychological factors on the 
development of breast cancer.  Already Galen expressed the notion that psychological factors 
play a role in the development of cancer [2]. The author of the first statistical report relating 
cancer to psychological distress concluded that the cases in which breast cancer immediately 
follows depressive emotions were too great to be caused by chance [3].  Most modern theories 
proposing an influence of depression on the development of breast cancer hypothesize reduced 
immune function as the connecting factor between depression and breast cancer.  In other words, 
depression impairs immune function, which in turn, predisposes an individual to the 
development of cancer [4].  These theories are supported by studies finding reduced numbers and 
functional measures of immunity in depressed individuals [5,6].  Another possible biological 
mechanism connecting depression with the development of breast cancer is that depression 
inhibits DNA repair mechanisms and, therefore, defense against cancer growth [7,8].  A final 
way in which depression might increase the risk of breast cancer is by causing an aberrant 
activity of the hypothalamic–pituitary–adrenal axis leading to a dysregulation of the stress 
hormone cortisol. Cortisol is involved in the control of cell growth and regulation of the cell 
cycle which explains why a flattening of cortisol levels throughout the course of a day has been 
shown to increase the risk for breast cancer [9-11]. 
Despite the high face-validity of the aforementioned theoretical explanations for the 
proposed association between depression and the development of breast cancer and more than 30 
years of empirical research, including several published reviews, a clear connection, or the lack 
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thereof, between the presence of depression and the development of breast cancer has not been 
established [12-18]. Possible reasons for inconsistent results include insufficient consideration of 
growth rates of breast cancer and inadequate assessment of depression.  The purpose of this 
review is to examine these possible methodological problems as they relate to the study of the 
development, or initiation, of breast cancer and to estimate the associations between depression 
and development of cancer after controlling for these confounding factors as far as possible. 
Time Frame 
Multiple reviews of empirical studies demonstrated that it takes more than 18 years for 
breast cancer with an average Tumor Volume Doubling Time (TVDT) of 280 days to grow from 
the first tumor cell to a tumor that is detectable [19-20]. This growth rate suggests that studies 
with time frames of less than 18 years are inadequate for examining the influence of major 
depression on the development of cancer; therefore, predictive associations are likely to be 
underestimated. 
Thus, because this review seeks to illuminate the causative role in breast cancer, this 
review will focus only on studies utilizing a prospective design. Some interpret the pre-bioptic 
study design, which is used in some studies focusing on breast cancer, as a variation of the 
prospective design. These studies investigate people who come for diagnostic tests but do not yet 
know whether or not they have cancer [21-25]. Such patients often make guesses about their 
medical condition, and these expected diagnoses may influence their responses to measures of 
depression [14]. These studies are limited in their ability to evaluate causality and are not able to 
fully evaluate psychological variables in participants prior to the confirmation of benign, 
malignant or no breast disease under similar conditions; therefore, they will not be included in 
this review. 
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Assessment of depression 
Deciding which symptoms are part of depression and which may be attributable to cancer 
is complex. There is evidence to suggest that the inclusion of somatic items may overestimate the 
association between depression and cancer. For example, one study explored the role of somatic 
items in the diagnosis of depression in cancer patients by dividing the Zung Self-Rating scale 
into a questionnaire with and without somatic items. The questionnaire with somatic items 
produced 5% more false-positive depressed cancer patients [26]. In addition, Wedding et al. [27] 
analyzed the extent to which the prevalence of major depression or depressive symptoms in 
cancer patients was related to somatic or affective items of the Beck Depression Inventory when 
compared to healthy controls. They found that major depression and depressive symptoms were 
mainly related to somatic, not affective, items and that differences compared to a healthy control 
group existed mainly in the somatic items. In light of this, Endicott [28] suggested substituting 
poor appetite disturbance, sleep disturbance, fatigue/loss of energy, and diminished ability to 
concentrate/indecisiveness. Other authors [29], however, conclude that, while somatic symptoms 
of depression are less useful than affective and cognitive symptoms, they could be used if they 
were severe and proportionate to the cancer stage. In addition, cultural differences in the 
expression of depression need to be considered. For example, somatic symptoms of depression 
are more clearly manifest in Asian cultures than affective and cognitive symptoms [30].  Thus, it 
would be important to identify the role somatic symptoms play in regards to the measured 
association between depression and breast cancer. To study this problem,  the following 
symptoms, put forth as diagnostic criteria for a major depressive episode in the Diagnostic and 
Statistical Manual of Mental Disorders (4th ed.; DSM-IV) [31] were categorized as somatic: 
appetite disturbance, sleep disturbance, fatigue/loss of energy, and diminished ability to 
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concentrate/ indecisiveness [28,32]. Other depression symptoms encountered in this review were 
considered to be somatic if they were categorized as such by the measurement scale being used 
(e.g., Zung Rating Depression Scale) [33]. 
Method 
This review explores the evidence regarding whether major depression plays a causal role 
in the development of breast cancer; therefore, we have focused only on studies utilizing a 
prospective design (i.e., assess depression at one point in time, and cancer at a second, later point 
in time).  A literature search was conducted using Academic Search Premier, Medline, 
Psychology and Behavioral Sciences Collection, and PsycINFO. Key words were depress* + 
cancer, neoplasm, or tumor + longitudinal, or prospective + breast in January 2012.  Secondary 
searches were conducted through the references lists of relevant reviews and meta-analyses [12-
18].  These searches identified 481 reports; however, after removing duplicates, screening the 
reports, assessing them for eligibility, and excluding all articles that did provide an indication of 
the direction of the effect, 15 reports remained (see Figure 1).  Time frame, assessment of 
depression, analytical sample size, and incidence of breast cancer of these reports are described 
in Table 1.  In those reports that presented separate data for males and females, analytical sample 
size and incidence of breast cancer are presented for females only. 
Meta-analysis usually involves computing a weighted average effect size that represents 
the magnitude of the relations of interest.  This procedure presumes that the standard errors for 
the effect sizes have the same conceptual meaning.  Regression-based studies are challenging in 
this regard, because conceptually similar variables are rarely controlled across studies.  This 
means that the population effects actually have different conceptual meanings across the studies, 
and unless the evidence base has a very large number of studies, meta-analysis would be difficult 
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due to the number of sparse or empty cells.  Furthermore, prospective studies sometimes present 
data in ways that make combining effect sizes across studies more difficult. For example, some 
studies might carry out time-to-event analyses while others measure cross-sectional effects.    
Given the conceptual differences in the meaning of effects across studies that examine 
the prospective relation between depression and breast cancer, we could not rely on traditional 
meta-analytic procedures.  Instead, we conducted a weighted vote count of the directions of the 
effect [34].  Taking into account the sample sizes from the individual studies, this procedure 
exploits information about the proportion of positive to negative effects to bootstrap an estimate 
of an overall weighted average effects size and its confidence interval.  It is a more conservative 
procedure in the sense that the resulting confidence intervals are wider than those that would 
arise from a more ideal analysis (e.g., a meta-analysis of regression coefficients based on models 
of exactly the same covariates across studies). 
Results 
Eighteen prospective studies, covering over 600,000 participants, were dedicated to 
investigating the risk of breast cancer incidence associated with depression.  Of these 18 studies, 
three studies did not give an indication of the direction of the effect [35-37].  In other words, the 
authors simply stated that the results were not statistically significant and provided no clues 
regarding the sign of the effect.  These three studies could not be used in the following analyses.  
Of the 15 studies providing information about the direction of the effect, twelve were positive 
(i.e., depression was associated with higher breast cancer incidence)1, while three were negative.  
Assuming equal weights across studies (specifically, the harmonic mean sample size of 4,309), 
the estimated correlation is r = +.04.  Taking sample size of the individual studies into account, 
                                                 
1 It should be noted that Gross et al.’s [49] publication is an update of Gallo et al. [47] including an additional wave 
of data collection which extends the time frame from 13 to 24 years. In addition, both studies use only partially 
identical methodological control variables. 
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the estimated correlation is r ≈+.025 ± .027 (95% Confidence Interval).  Thus, the correlation is 
not significantly different from zero. 
As discussed above, these estimates are associated with uncertainty due to the potential 
influence of different methodological problems (i.e., time frame between the assessment of 
depression and cancer, assessment of depression).  Below we present data on how the different 
methodological issues were related to the effects observed in the studies.  Ideally, we would have 
been able to conduct a moderator analysis to determine if these observed differences in rates 
were indicative of real differences in rates attributable to the study characteristics.  In many 
cases, however, the presence of empty cells made these analyses impossible.  Consequently, we 
show how different methodological choices are associated with estimated effects for some 
variables; for others, we were unable to carry out this analysis. 
Time Frame 
The time frame necessary to study the influence of depression on breast cancer is more 
than 18 years [19].  Although we recognize that the cost and time associated with conducting a 
study with 18+ years of follow-up would be substantial, this length of follow-up is considered 
ideal for empirical study.  Of the 15 breast cancer studies in our analysis, only five had a time 
frame of more than 18 years (ranging from 24 to 33 years).  Six studies had a time frame 
between 10 and 18 years, and four studies had a time frame of less than 10 years (Table 1).  
Separating the studies based on the time frame revealed that 100% (5 of 5 studies) of the studies 
with appropriate time frame (i.e., >18 years) found positive associations between depression and 
breast cancer.  Of the studies with shorter time frames, 70% (7 of 10 studies) found positive 
associations between depression and breast cancer incidence rates. 
Assessment of depression 
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The studies included in this review were appraised according to their use of somatic 
symptoms in assessing major depression.  There was extreme variability in the methods used by 
the studies to assess for depression (See Table 1), and the instruments used varied significantly in 
the number and percentage of somatic items they contained (0% to 44%, Table 2).  Only one of 
the 15 studies reviewed utilized assessment methods that did not include any somatic items [48]. 
Eleven studies, on the other hand, utilized instruments that were more than 20% somatic items. 
Of the studies that utilized instruments with less than 20% somatic items, 33.3% (1 of 3) 
found positive and 66.6% (2 of 3) found negative associations between depression and breast 
cancer.  Of the studies that utilized instruments with more than 20% somatic items, 90.9% (10 of 
11) found positive associations, while only 9.1% (1 of 11) study found negative associations 
between depression and breast cancer.  This difference suggests that somatic items may result in 
an overestimation of the association between depression and breast cancer. 
Discussion 
The purpose of this review was to examine the effects of (a) insufficient time frame and 
(b) assessment of depression including somatic items on the study of the development of breast 
cancer.  It was expected that an insufficiently long time frame would lead to an underestimation 
of the association between depression and cancer, while the inclusion of somatic items in the 
assessment of depression would lead to an overestimation of the association between depression 
and breast cancer. 
Using sample size as a weight, the estimated predictive associations between depression 
and development of breast cancer incidence is approximately r = +.025  ± .027 (95% Confidence 
Interval).  Thus, the estimated predictive associations are not significant.  This estimate is 
associated with additional uncertainty, however, due to the possibility of the discussed 
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methodological problems.  Therefore, we examined how the proportion of positive (12 studies) 
and negative effects (3 studies) varied as a function of studies scoring “well” vs. “not well” on 
two dimensions.  These findings were as predicted.  Not only did a short time frame appear to 
underestimate the association, but every study with an appropriate time frame found a positive 
association between depression and breast cancer incidence.  Furthermore, studies utilizing 
measures of depression with higher percentage of somatic items were more likely to find positive 
associations than studies with lower percentage of somatic items. 
Clearly, the current review has limitations.  All studies we identified relied on a single 
diagnosis or assessment of depressive symptoms.  A hypothesis linking depression and breast 
cancer development presumably implies some element of chronicity; therefore, a one-time 
assessment of depression with no measure of duration weakens the test of any such hypothesis 
[15].  Evidence regarding the differential effects of short vs. long-term depression comes from a 
study evaluating the impact of a single episode of Major Depression, recurrent episodes of Major 
Depression, and Dysthymia on the development of breast cancer [41].  Single and recurrent 
episodes of Major Depression did not significantly predict the development of breast cancer in 
this study; however, Dysthymia did.  This is interesting since an episode of Major Depression 
requires more symptoms, but it can be as short as two weeks.  Dysthymia, on the other hand, 
requires fewer symptoms, but the symptoms need to be present for at least two years.  A related 
issue is the need for more thorough psychological assessment that includes different trait and 
state-like constructs.  Stable constructs like cognitive risk factors of depression may account for 
more variance in health-related outcomes than do episodic bouts of depressive symptomatology 
(i.e., episode of Major Depression).  For example, rumination, a trait-like cognitive style in 
which individuals respond to a sad mood by repetitively focusing their attention on their mood 
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and implications of the mood, does not only prolong depressive mood [52] but is also associated 
with the immune suppressive hormone cortisol, even after controlling for depressive symptoms 
[53]. 
Regarding our methods, one drawback to the weighted vote count approach is that, 
relative to a more traditional meta-analysis of effect sizes, it has lower statistical power (i.e., 
confidence intervals arising from a weighted vote count will be wider).  A second potential 
problem is that this procedure uses a fixed effect model, and if that model is inappropriate, the 
resulting confidence intervals could be spuriously narrow.  Future systematic reviews and meta-
analyses would benefit from additional studies that allow for a reasonable amount of time 
between the assessments of depression and cancer.  Although it would be resource intensive, a 
meta-analysis involving individual participant data would be a valuable contribution to this area 
of research. It would allow reviewers to create conceptually similar groups of effect sizes to 
better explore both the link between depression and breast cancer as well as the impact of certain 
methodological choices. 
Another direction for future research is to evaluate the impact of other risk factors and 
regulators on the association between depression and the development of breast cancer.  When 
other potential risk factors and regulators are not identified, measured, and controlled for by 
appropriate design or statistical techniques, they can bias the results of a study, leading 
researchers to make erroneous conclusions.  Thus, methodological control has a substantial 
influence on the empirical findings of a study.  Certain variables (e.g., smoking), however, are 
likely to be stronger confounders than other variables (e.g., alcohol consumption).  Thus, 
systematic reviews should categorize potential confounders and then evaluate their impact on the 
association between depression and development of breast cancer. 
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Finally, it needs to be considered that all three studies finding negative associations 
between depression and breast cancer incidence [33, 39, 43] and six studies finding positive 
associations [40-42, 44, 47, 48] included fewer than 220 individuals that developed breast 
cancer, while all studies finding positive associations had numbers of individuals developing 
breast cancer ranging from 229 to 2,892 cases of breast cancer [38, 45, 46, 49-51].  Thus, the 
small number of breast cancer cases could be another explanation for the negative associations 
between depression and breast cancer incidence. 
In summary, twelve studies included in the review found positive associations between 
depression and breast cancer incidence while three studies found negative associations.  The vote 
count revealed relations between depression and breast cancer that, while not statistically 
significant, were large enough to be meaningful at a population level.  Perhaps even more 
important is our observation that the existing literature related to depression and the development 
of breast cancer revealed significant problems concerning time frame and the measures used to 
assess depression.  The findings related to the predictive associations between depression and 
breast cancer incidences revealed that (a) studies with inappropriate short time frame 
underestimate the association and (b) utilizing measures of depression with somatic items 
overestimate positive associations.  Although there is evidence that depression is positively 
associated with breast cancer incidence, the current literature does not allow for definitive 
conclusions. 
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Table 1. Summary of studies examining depression and the development of breast cancer 
included in the analyses 
Study Author(s) & Year Time Frame 
 (in years) 
Depression measure Analytical 
sample/incidence of 
breast cancer 
Bleiker et al. [33] 13 Zung Rating Scales 
for Depression 
9,705/217a 
Goldacre et al. [38] 33 ICD 7-10 276,627c/229a 
Nykliček et al. [39] 5 EDI 5,191/58a 
Gallo et al. [40] 13 DIS 1,213/25a 
Gross et al. [41] 24 DIS 3,481/50a 
Jacobs & Bovasso [42] 15 DIS 1,213/39a 
Lichtman [43] 6 CES-D 1,458/26a 
Hahn & Petitti [44]  15 to 18 MMPI-1 8,932/117a 
Hjerl et al. [45] 24 ICD 8 66,648/1,270a 





Kaplan & Reynolds [47] 17 HPL 6,848/77b 
Knekt et al. [48] 14 GHQ 3,773/210a 
Chen & Lin [49] 5 ICD 9 4,668/273b 
Liang et al. [50] 8 ICD 9 75,771/2,892b 
Schuurman et al. [51] 25 ICHPPC-2 68,366/728b 
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Note: MMPI-1 = Minnesota Multiphasic Personality Inventory -1st edition, HPL = Human 
Population Laboratory, CES-D = Center for Epidemiological Studies-Depression, GHQ = 
General Health Questionnaire, ICD = International Classification of Diseases, DIS = Diagnostic 
Interview Schedule, EDI = Edinburgh Depression Inventory, ICHPPC-2 = International 
Classification of Health Problems in Primary Care, a = females only, b = females and males, c = 
Goldacre et al. report an overall sample size of n = 553,254 and to calculate the analyses with 
breast cancer with female participants only. However, they do not report the number females in 
their sample. Thus, for the purpose of the weighted vote count, we estimated the sample would 
include 50% female participants.  
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Effect size and 





and breast cancer 
Bleiker et al. [33] 13 10 out of 20 0.75 (0.52-1.07)b Negative 
Goldacre et al. [38] 33 2 out of 6 0.92 (0.80-1.05)c Positive 
Nykliček et al. [39] 5 1 out of 10 0.29 (0.09-0.92)b Negative 
Gallo et al. [40] 13 4 out of 8 3.8 (0.5-3.4)d Positive 
Gross et al. [41] 24 4 out of 8 1.87(1.16-3.01)a Positive 
Jacobs & Bovasso 
[42] 
15  4 out of 8 17.2 (3.76-78.08)b Positive 
Lichtman [43] 6 3 out of 20 0.9 (NR)b Negative 
Hahn & Petitti [44]  15 to 18  14 out of 57 1.5 (0.9-2.5)d Positive 
Hjerl et al. [45] 24 2 out of 6 1.02 (0.97-1.08)e Positive 
Dalton, 
Mellemkjaer et al. 
[46] 
24 2 out of 6 1.06 (0.98-1.15)e Positive 
Kaplan & 
Reynolds [47] 
17 4 out of 18 1.13 (NR)d Positive 
Knekt et al. [48] 14  0 out of 18 1.65 (0.60-4.58)d Positive 
Chen & Lin [49] 5 2 out of 6 1.25 (0.42-3.76)a Positive 
Liang et al. [50] 8 2 out of 6 1.09 (0.78-1.53)a Positive 
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Schuurman et al. 
[51] 
25 1 out of 6 1.06 (0.71-1.58)a Positive 
Note: a = hazard ratio; b = odds ratio; c = rate ratio; d = relative risk; e = standardized incidence 
ratio; (NR) = confidence interval not reported; Positive = positive association between 
depression and cancer; Negative = negative association between depression and cancer.  





Figure 1: Flowchart for the literature screening process. 
488 records identified through 
database searching 
26 additional records identified 
through other sources 
277 records after duplicates removed 
277 records screened 
Records excluded 
22 not empirical 
34 not longitudinal 
192 not development 
of cancer 
29 full-text articles 
assessed for eligibility 
18 studies included in 
qualitative synthesis  
Full-text articles 
excluded, because  
5 not breast cancer 
4 psychological 
factors other than 
depression 
2 not development of 
cancer 
15 studies included in 
quantitative synthesis 
(meta-analysis) 
3 articles excluded, 
because they did not 
provide information 
on direction of 
association 
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